IP Library Granted Patent US 12,275,992
Granted Patent B2
US 12,275,992 · App. 17/741,708 · Granted Apr 15, 2025

Characterization of molecules in nanofluidics

Inventors: Han Cao (San Diego, CA); Alex R. Hastie (San Diego, CA); Ernest Tsz-Tsun Lam (San Diego, CA)
Assignee: Bionano Genomics, Inc.
C12Q1/6883B01L3/5027C12Q1/6809G01N33/5091G16B30/00G16B30/10B01L2200/10B01L2300/0627C12Q2600/166
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,275,992
App. No.
17/741,708
Granted
Apr 15, 2025
Kind
B2
Abstract

Systems are provided for detecting and quantitating short nucleic acid molecules.

Claims (30)

1. A method of detecting a tumor cell in a sample comprising polynucleotide sequences, the method comprising:

labeling a plurality of sequence-specific locations on a polynucleotide sequence of a sample molecule of less than 1000 nucleotides in length;

linearizing at least a portion of the sample molecule in a fluidic nanochannel,

wherein the fluidic nanochannel has a length of at least 10 nm and cross sectional diameter of less than 1000 nm;

quantifying a signal from the labels on the sample molecule; and

comparing a quantity of the signal from the sample molecule to a quantity of signal from a reference molecule of less than 1000 nucleotides in length, wherein a difference between the signal of the sample molecule and the signal of the reference molecule is indicative of the presence or absence of a tumor cell in the sample.

2. The method of claim 1 , wherein the sample is derived from a tumor cell, suspected of comprising circulating tumor cells, or derived from a tissue in fluid communication with a tumor cell.

3. The method of claim 1 , wherein the reference molecule is from a healthy cell.

4. The method of claim 1 , wherein the quantity of the signal comprises coverage depth.

5. The method of claim 4 , further comprising generating a histogram distribution to reflect coverage depth for the sample.

6. The method of claim 1 , wherein the sample molecule and the reference molecule are from different tissues of the same organism.

7. The method of claim 1 , wherein the labeling comprises labeling the sample molecule with at least two labels located at either end of a zone of interest in the sample molecule.

8. The method of claim 1 , wherein the quantity of signal from the reference molecule comprises an electronically or optically stored value or set of values.

9. The method of claim 1 , wherein comparing the quantity of the signal from the sample molecule to the quantity of signal from the reference molecule comprises generating a histogram distribution to reflect coverage depth for the sample.

10. The method of claim 1 , wherein comparing the quantity of the signal from the sample molecule to the quantity of signal from the reference molecule comprises using the ratio (K) between the signal arising from a plurality of samples or sample portions (S1, S2 . . . Sn) and the signal arising from the reference molecule (C):

K 1= S 1/ C, K 2= S 2/ C . . . Kn=Sn/C.

11. The method of claim 10 , wherein a difference between K1 and Kn is used to determine the presence of a tumor cell in the sample.

12. The method of claim 1 , wherein the polynucleotide sequence of the sample molecule comprises less than 550 nucleotides in length.

13. A system for detecting a tumor cell in a sample, comprising:

a fluidic nanochannel for translocating labeled sample nucleic acid molecules of less than 1000 nucleotides in length, wherein the fluidic nanochannel has a length of at least 10 nm and cross sectional diameter of less than 1000 nm, wherein the fluidic nanochannel is configured to elongate at least a portion of the labeled sample nucleic acid molecules, and wherein the sample nucleic acid molecules are labeled while being less than 1000 nucleotides in length; and

a device configured to detect physical counts of signals arising from the labeled sample nucleic acid molecules of less than 1000 nucleotides in length in the fluidic channels.

14. The system of claim 13 , wherein the sample comprises circulating tumor cells, body fluids, or tissues, or is suspected of comprising circulating tumor cells.

15. The system of claim 13 , wherein the system is configured to correlate signals arising from the labeled sample nucleic acid molecules to signals arising from the corresponding region of a reference molecule.

16. The system of claim 13 , wherein the signals arising from a known corresponding region of a reference molecule are the signals arising from a labeled reference molecule.

17. The system of claim 13 , wherein correlating the signals comprises determining the signals arising from a pool of samples or a pool of portions of a sample.

18. The system of claim 13 , wherein the system is configured to correlate the signals comprises using the ratio (K) between the signal arising from a plurality of samples or sample portions (S1, S2 . . . Sn) and the signal arising from the reference (C):

K 1= S 1/ C, K 2= S 2/ C . . . Kn=Sn/C.

19. The system of claim 18 , wherein a difference between K1 and Kn is used to determine the presence of a nucleic acid from a tumor cell in the sample.

20. The system of claim 13 , wherein the system is configured to generate a histogram distribution to reflect coverage depth for the sample.

21. The system of claim 13 , wherein the detecting comprises optical inspection comprising determining the physical count, the intensity, the wavelength, or the size of the labels, and wherein the detecting comprises optical inspection comprising determining the length of at least one labeled region in the sample.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded May 24, 2024
From: HIGH TRAIL SPECIAL SITUATIONS LLC, AS COLLATERAL AGENT
To: BIONANO GENOMICS, INC.
Reel/Frame 067529/0193 →
SECURITY INTEREST Recorded May 24, 2024
From: BIONANO GENOMICS, INC.; BIODISCOVERY, LLC; LINEAGEN, INC.; PURIGEN BIOSYSTEMS, INC.
To: JGB COLLATERAL, LLC
Reel/Frame 067529/0286 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 16, 2023
From: BIONANO GENOMICS, INC.
To: HIGH TRAIL SPECIAL SITUATIONS LLC
Reel/Frame 065241/0844 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 11, 2022
From: CAO, HAN; HASTIE, ALEX R.; LAM, ERNEST TSZ-TSUN
To: BIONANO GENOMICS, INC.
Reel/Frame 059891/0661 →
Continuity (5)
Continuation 16887679 · May 29, 2020
Continuation 15795847 · Oct 27, 2017
Continuation 14768422
Provisional Application 61767219 · Feb 20, 2013
Related Publication 20220340973A1 · Oct 27, 2022
References Cited (105)
US 8628919B2 · Xiao et al. · 2014 [cited by applicant]
US 8722327B2 · Cao et al. · 2014 [cited by applicant]
US 9310376B2 · Cao et al. · 2016 [cited by applicant]
US 9809855B2 · Cao et al. · 2017 [cited by applicant]
US 10000804B2 · Cao et al. · 2018 [cited by applicant]
US 20030104428A1 · Branton et al. · 2003 [cited by applicant]
US 20040197843A1 · Chou et al. · 2004 [cited by applicant]
US 20060063184A1 · Felix et al. · 2006 [cited by applicant]
US 20080242556A1 · Cao et al. · 2008 [cited by applicant]
US 20090305273A1 · Cao et al. · 2009 [cited by applicant]
US 20100285082A1 · Fernandez · 2010 [cited by applicant]
US 20110117577A1 · Reboud et al. · 2011 [cited by applicant]
US 20110171634A1 · Xiao et al. · 2011 [cited by applicant]
US 20110229888A1 · Hengen et al. · 2011 [cited by applicant]
US 20110296903A1 · Cao et al. · 2011 [cited by applicant]
US 20110306504A1 · Xiao et al. · 2011 [cited by applicant]
US 20120095697A1 · Halpern et al. · 2012 [cited by applicant]
US 20120097835A1 · Sharonov · 2012 [cited by applicant]
US 20120100600A1 · Slepnev · 2012 [cited by applicant]
US 20120108920A1 · Bly et al. · 2012 [cited by applicant]
US 20120237936A1 · Xiao et al. · 2012 [cited by applicant]
US 20120244635A1 · Austin et al. · 2012 [cited by applicant]
US 20130034546A1 · Rava et al. · 2013 [cited by applicant]
US 20130036860A1 · Xiao et al. · 2013 [cited by applicant]
US 20130055817A1 · Maeda et al. · 2013 [cited by applicant]
US 20130072386A1 · Xiao et al. · 2013 [cited by applicant]
US 20130085681A1 · Deciu et al. · 2013 [cited by applicant]
US 20130103320A1 · Dzakula et al. · 2013 [cited by applicant]
US 20130150253A1 · Deciu et al. · 2013 [cited by applicant]
US 20130261983A1 · Dzakula et al. · 2013 [cited by applicant]
US 20130309666A1 · Deciu et al. · 2013 [cited by applicant]
US 20130325360A1 · Deciu et al. · 2013 [cited by applicant]
US 20130338933A1 · Deciu et al. · 2013 [cited by applicant]
US 20140014497A1 · Druz et al. · 2014 [cited by applicant]
US 20140099642A1 · Jiang et al. · 2014 [cited by applicant]
US 20160046992A1 · Cao et al. · 2016 [cited by applicant]
WO WO2008079169 · 2008 [cited by applicant]
WO WO2008121828 · 2008 [cited by applicant]
WO WO2009149362 · 2009 [cited by applicant]
WO WO2010002883 · 2010 [cited by applicant]
WO WO2010059731 · 2010 [cited by applicant]
WO WO2010135323 · 2010 [cited by applicant]
WO WO2011038327 · 2011 [cited by applicant]
WO WO2011050147 · 2011 [cited by applicant]
WO WO2011109762A1 · 2011 [cited by examiner]
WO WO2012054735 · 2012 [cited by applicant]
WO WO2012108920 · 2012 [cited by applicant]
WO WO2013000100 · 2013 [cited by applicant]
WO WO2013036860 · 2013 [cited by applicant]
WO WO2013052907 · 2013 [cited by applicant]
WO WO2013052913 · 2013 [cited by applicant]
WO WO2013055817 · 2013 [cited by applicant]
WO WO2013109981 · 2013 [cited by applicant]
WO WO2013166517 · 2013 [cited by applicant]
WO WO2013177086 · 2013 [cited by applicant]
WO WO2013192562 · 2013 [cited by applicant]
WO WO2014014497 · 2014 [cited by applicant]
WO WO2014123822 · 2014 [cited by applicant]
WO WO2014130589 · 2014 [cited by applicant]
U.S. Appl. No. 61/713,862, filed Oct. 15, 2012, Saghbini et al. [cited by applicant]
U.S. Appl. No. 61/734,327, filed Dec. 6, 2012, Saghbini et al. [cited by applicant]
Chao & Tammi, “CNV-seq, a new method to detect copy number variation using high-throughput sequencing,” BMC Bioinformatics 2009, 10(80), doi:10.1186/1471-2105-10-80, in 9 pages. [cited by applicant]
Examination Report dated Apr. 26, 2018 in European Patent Application No. 14753475.4. [cited by applicant]
Examination Report dated Mar. 7, 2019 in European Patent Application No. 14753475.4. [cited by applicant]
Extended European Search Report dated Jul. 14, 2016 in European Patent Application No. 14753475.4. [cited by applicant]
Final Office Action dated Jul. 16, 2019 in U.S. Appl. No. 15/795,847. [cited by applicant]
Final Office Action dated Oct. 23, 2019 in U.S. Appl. No. 15/117,689. [cited by applicant]
International Preliminary Report on Patentability dated Aug. 30, 2016 in PCT Application No. PCT/US2015/017356. [cited by applicant]
International Preliminary Report on Patentability dated Apr. 10, 2015 in PCT Application No. PCT/US2014/017226. [cited by applicant]
International Search Report and Written Opinion dated Jun. 10, 2015 in PCT Application No. PCT/US2015/017356. [cited by applicant]
International Search Report and Written Opinion dated May 30, 2014 in PCT Application No. PCT/US2014/017226. [cited by applicant]
Jensen et al., “Detection of Microdeletion 22q11.2 in a Fetus by Next-Generation Sequencing of Maternal Plasma,” Clinical Chemistry 2012, 58(7), 1148-1151. [cited by applicant]
Jensen et al., “High-Throughput Massively Parallel Sequencing for Fetal Aneuploidy Detection from Maternal Plasma,” PLoS One 2013, 8(3), e57381, in 8 pages. [cited by applicant]
Kidd et al., “Mapping and sequencing of structural variation from eight human genomes,” Nature 2008, 453, 56-64. [cited by applicant]
Lam et al., “Genome mapping on nanochannel arrays for structural variation analysis and sequence assembly,” Nature Biotechnology 2012, 30(8), 771-776. [cited by applicant]
Mazloom et al., “Noninvasive prenatal detection of sex chromosomal aneuploidies by sequencing circulating cell-free DNA from maternal plasma,” Prenatal Diagnosis 2013, 33, 591-597. [cited by applicant]
Nord et al., “Accurate and exact CNV identification from targeted high-throughput sequence data,” BMC Genomics 2011, 12(184), 1-10. [cited by applicant]
Non-Final Office Action dated Oct. 26, 2016 in U.S. Appl. No. 14/768,422. [cited by applicant]
Non-Final Office Action dated Dec. 11, 2018 in U.S. Appl. No. 15/795,847. [cited by applicant]
Non-Final Office Action dated Feb. 27, 2019 in U.S. Appl. No. 15/117,689. [cited by applicant]
Non-Final Office Action dated Nov. 9, 2021 in U.S. Appl. No. 16/887,679. [cited by applicant]
Notification of Reasons for Refusal dated Oct. 16, 2018 in Japanese Patent Application No. 2015-558929. [cited by applicant]
Notification of Reasons for Refusal dated Jan. 30, 2018 in Japanese Patent Application No. 2015-558929. [cited by applicant]
Notice of Allowance dated Jul. 6, 2017 in U.S. Appl. No. 14/768,422. [cited by applicant]
Notice of Allowance dated Apr. 26, 2019 in Japanese Patent Application No. 2015-558929. [cited by applicant]
Notice of Allowance dated Jan. 23, 2020 in U.S. Appl. No. 15/795,847. [cited by applicant]
Notice of Allowance dated Apr. 17, 2020 in Chinese Patent Application No. 201480009730.6. [cited by applicant]
Notice of Allowance dated Apr. 30, 2020 in Chinese Patent Application No. 201580016272.3. [cited by applicant]
Notice of Allowance dated May 18, 2020 in European Patent Application No. 14753475.4. [cited by applicant]
Notice of Allowance dated Jul. 28, 2020 in U.S. Appl. No. 15/117,689. [cited by applicant]
Notice of Allowance dated Jul. 6, 2021 in Japanese Patent Application No. 2019-110164. [cited by applicant]
Notice of Allowance dated Mar. 7, 2022 in U.S. Appl. No. 16/887,679. [cited by applicant]
Office Action dated Oct. 24, 2016 in Chinese Patent Application No. 201480009730.6. [cited by applicant]
Office Action dated Jun. 14, 2018 in Chinese Patent Application No. 201480009730.6. [cited by applicant]
Office Action dated Sep. 20, 2017 in Chinese Patent Application No. 201480009730.6. [cited by applicant]
Office Action dated Mar. 29, 2019 in Chinese Patent Application No. 201580016272.3. [cited by applicant]
Office Action dated Jan. 2, 2020 in Chinese Patent Application No. 201580016272.3. [cited by applicant]
Office Action dated Jan. 27, 2020 in Canadian Patent Application No. 2,901,460. [cited by applicant]
Office Action dated Jul. 21, 2020 in Japanese Patent Application No. 2019-110164. [cited by applicant]
Office Action dated Feb. 5, 2021 in Canadian Patent Application No. 2,901,460. [cited by applicant]
Office Action dated Feb. 7, 2022 in Canadian Patent Application No. 2,901,460. [cited by applicant]
Oldridge et al., “Optimizing copy number variation analysis using genome-wide short sequence oligonucleotide arrays,” Nucleic Acids Research 2010, 38(10), 3275-3286. [cited by applicant]
Schouten et al., “Platform comparisons for identification of breast cancers with a BRCA-like copy number profile,” Breast Cancer Research and Treatment 2013, 139, 317-327. [cited by applicant]
Stavis et al., “Single-molecule mobility and spectral measurements in submicrometer fluidic channels,” Journal of Applied Physics 2005, 98(044903), in 5 pages. [cited by applicant]
Yahya-Graison et al., “Classification of Human Chromosome 21 Gene-Expression Variations in Down Syndrome: Impact on Disease Phenotypes,” The American Journal of Human Genetics 2007, 81, 475-491. [cited by applicant]